A landmark expansion: Samsung Biologics secures U.S. manufacturing base to enhance resilience of global biologics supply chain
ROCKVILLE/SEOUL — In a major strategic development for the international biopharmaceutical sector, Samsung Biologics has signed a definitive agreement to acquire Human Genome Sciences from GSK — a move that instantly grants the South Korean giant its first manufacturing site in the United States and strengthens long-term supply security for critical biologic medicines.
Positioned in Maryland’s thriving life sciences corridor, the Rockville facility offers sophisticated infrastructure, including two cGMP-certified plants capable of producing biologic drug substances at 60,000 liters capacity. Samsung Biologics will preserve existing operations while embarking on infrastructure upgrades designed to expand output, embed new manufacturing technologies and bolster national health preparedness.
Retaining the existing workforce of over 500 professionals ensures continuity of expertise and safeguards institutional knowledge, while offering new career development opportunities under Samsung’s global innovation framework.
According to CEO John Rim, the acquisition underscores Samsung Biologics’ unwavering ambition to deepen engagement with the United States — the world’s largest and most influential biopharma market. He emphasised the company’s intention to collaborate closely with federal, state and local stakeholders to ensure biosupply resilience, accelerate innovation, and strengthen national medical security.
Beyond infrastructure growth, this acquisition symbolises an important industrial evolution: the increasing interconnectedness between Asian innovation powerhouses and the U.S. healthcare economy. Samsung Biologics’ proven execution track record — highlighted by its vast 785,000-liter global capacity — positions the company as a critical manufacturing ally for American healthcare priorities.
For GSK, divesting the Rockville facility supports strategic restructuring, allowing stronger focus on research, vaccines and specialty medicine innovation. The company noted that the deal complements its ongoing multi-billion-dollar R&D commitments within the U.S. over the next five years.
From a wider perspective, the acquisition arrives at a time when global supply chain reliability remains a pressing concern. The COVID-19 pandemic exposed vulnerabilities across international pharmaceutical logistics. By increasing localized manufacturing capability within the U.S., Samsung Biologics contributes to a more geographically balanced and crisis-resilient production landscape.
The deal is expected to close toward the end of Q1 2026. Upon completion, the Rockville facility will serve as a cornerstone in Samsung Biologics’ diversified global network — reinforcing its leadership in cutting-edge biologics such as monoclonal antibodies, ADC therapies, mRNA platforms and emerging future medical technologies.
Ultimately, the acquisition represents more than an expansion. It is a commitment — to innovation, to patients, to collaboration, and to the long-term strengthening of one of the world’s most critical healthcare supply systems.